Novo Nordisk Narrows Saxenda’s Positioning, Targets Seriously Ill Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The Danish diabetes specialist is preparing to diversify into obesity with the first launches of Saxenda expected in the first half of 2015. Competition is expected to increases for GLP-1 market leader Victoza but Novo Nordisk also expects a more benign U.S. pricing environment during the year.